We have updated our terms and conditions and privacy policy. Click "Continue" to accept and continue to use ET HealthWorld

Dear users, ET HealthWorld's privacy and cookie policy has been updated to comply with the EU's new data regulations. Please review and accept these changes below to continue using the site. You can check our privacy policy and our cookie policy. We use cookies to ensure you get the best experience on our website. If you choose to ignore this message, we will assume that you are happy to receive all cookies on ET HealthWorld.

The last lap of COVID-19 vaccination requires active publicity: Mandavia 1 hour ago

India has reported 10,488 new COVID-19 cases in the past 24 hours, and the number of active cases is the lowest in 532 days 4 hours ago

Unsung heroes with faster overall recovery

Technological disruption in the health and pharmaceutical sectors in India

Do you think you are ready for the challenge?

A total solution for a healthier India

125,000 industry leaders read every day

The company has signed a voluntary licensing agreement with the pharmaceutical patent pool to help expand access to 95 low- and middle-income countries that account for approximately 53% of the world's population, pending authorization or approval. If approved, PAXLOVID™ (PF-07321332; Ritonavir) will be the first oral antiviral drug in its class, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2

Countries with the highest vaccination coverage are stockpiling more vaccines, and low-income countries are even struggling to obtain the first dose of vaccine for their populations.

We have a variety of advertising options, including events, advertisements, banners, emails, webinars, etc.

Please contact us for more details.

Get ETHealthworld headlines in your email inbox every morning.

125,000 industry leaders read every day

Follow @ETHealthworld for the latest news, internal visits, etc.